Most cited papers in Cancer therapeutics and mechanisms
What are the most cited papers in Cancer therapeutics and mechanisms?
The most cited paper in Cancer therapeutics and mechanisms is "Cisplatin in cancer therapy: Molecular mechanisms of action" (Shaloam R. Dasari, Paul Bernard Tchounwou, 2014), with 5,600 citations. Next come "Multidrug resistance in cancer: role of ATP–dependent transporters" (5,578) and "Cancer drug resistance: an evolving paradigm" (4,739).
Showing 50 of 100 papers. Every paper with more than 1,006 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Cisplatin in cancer therapy: Molecular mechanisms of action Shaloam R. Dasari, Paul Bernard Tchounwou · European Journal of Pharmacology | 21 Jul 2014 | 5,600 |
| 2 | Multidrug resistance in cancer: role of ATP–dependent transporters Michael M. Gottesman, Tito Fojo, Susan E. Bates · Nature reviews. Cancer | 2002 | 5,578 |
| 3 | Cancer drug resistance: an evolving paradigm Caitriona Holohan, Sandra Van Schaeybroeck, Daniel B. Longley et al. · Nature reviews. Cancer | 24 Sep 2013 | 4,739 |
| 4 | EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib Susumu S. Kobayashi, Titus J. Boggon, Tajhal Dayaram et al. · New England Journal of Medicine | 23 Feb 2005 | 3,981 |
| 5 | Targeting multidrug resistance in cancer Gergely Szakács, Jill K. Paterson, Joseph Aloysius Ludwig et al. · Nature Reviews Drug Discovery | Mar 2006 | 3,674 |
| 6 | Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Lecia Van Dam Sequist et al. · Science Translational Medicine | 23 Mar 2011 | 3,603 |
| 7 | Cisplatin: mode of cytotoxic action and molecular basis of resistance Zahid Hussain Siddik · Oncogene | 20 Oct 2003 | 3,351 |
| 8 | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial J-Y Douillard, David Cunningham, AD Roth et al. · The Lancet | Mar 2000 | 3,285 |
| 9 | FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study Christophe Tournigand, Thierry André, Emmanuel Achille et al. · Journal of Clinical Oncology | 8 Dec 2003 | 2,930 |
| 10 | The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway Michael R. Lieber · Annual Review of Biochemistry | 7 Jun 2010 | 2,911 |
| 11 | Molecular mechanisms of cisplatin resistance Lorenzo Galluzzi, Laura Senovilla, Ilio Vitale et al. · Oncogene | 5 Sep 2011 | 2,825 |
| 12 | Construction and characterization of new cloning vehicles. II. A multipurpose cloning system. F Bolivar, Raymond L. Rodriguez, P J Greene et al. · PubMed | 1977 | 2,772 |
| 13 | DNA Topoisomerases: Structure, Function, and Mechanism James J. Champoux · Annual Review of Biochemistry | Jun 2001 | 2,754 |
| 14 | The NCI60 human tumour cell line anticancer drug screen Robert H. Shoemaker · Nature reviews. Cancer | 22 Sep 2006 | 2,696 |
| 15 | Mechanisms of Cancer Drug Resistance Michael M. Gottesman · Annual Review of Medicine | Feb 2002 | 2,665 |
| 16 | Cellular roles of DNA topoisomerases: a molecular perspective James C. Wang · Nature Reviews Molecular Cell Biology | Jun 2002 | 2,368 |
| 17 | Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. Y H Hsiang, Robert Hertzberg, Sidney M. Hecht et al. · Journal of Biological Chemistry | Nov 1985 | 2,367 |
| 18 | Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Dominic A. Scudiero, Robert H. Shoemaker, Kenneth D. Paull et al. · PubMed | Sep 1988 | 2,362 |
| 19 | Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage Garrett M. Brodeur, Robert C. Seeger, Manfred Schwab et al. · Science | 8 Jun 1984 | 2,295 |
| 20 | Topoisomerase I inhibitors: camptothecins and beyond Yves G. Pommier · Nature reviews. Cancer | 22 Sep 2006 | 2,294 |
| 21 | A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin DavidA Gewirtz · Biochemical Pharmacology | Apr 1999 | 2,263 |
| 22 | Neuroblastoma: biological insights into a clinical enigma Garrett M. Brodeur · Nature reviews. Cancer | 28 Feb 2003 | 2,204 |
| 23 | A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis Koen Andries, Peter Verhasselt, Jérôme Guillemont et al. · Science | 9 Dec 2004 | 2,187 |
| 24 | The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Cai‐Hong Yun, Kristen E. Mengwasser, Angela V. Toms et al. · Proceedings of the National Academy of Sciences | 28 Jan 2008 | 2,150 |
| 25 | BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER Suresh V. Ambudkar, Saibal Dey, Christine A. Hrycyna et al. · The Annual Review of Pharmacology and Toxicology | Apr 1999 | 2,073 |
| 26 | Neuroblastoma John M. Maris, Michael D. Hogarty, Rochelle Bagatell et al. · The Lancet | Jun 2007 | 2,049 |
| 27 | Recent Advances in Neuroblastoma John M. Maris · New England Journal of Medicine | 10 Jun 2010 | 2,025 |
| 28 | Supercoiling of the DNA template during transcription. Leroy F. Liu, J C Wang · Proceedings of the National Academy of Sciences | Oct 1987 | 2,022 |
| 29 | The Different Mechanisms of Cancer Drug Resistance: A Brief Review Behzad Mansoori, Ali Mohammadi, Sadaf Davudian et al. · Advanced Pharmaceutical Bulletin | 25 Sep 2017 | 1,924 |
| 30 | Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Scott H. Kaufmann, Serge Desnoyers, Yvonne Lynn Ottaviano et al. · PubMed | Sep 1993 | 1,922 |
| 31 | Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy Edgar Pérez‐Herrero, Alberto Fernández‐Medarde · European Journal of Pharmaceutics and Biopharmaceutics | 2 Apr 2015 | 1,888 |
| 32 | DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs Yves G. Pommier, Elisabetta Leo, Hongliang Zhang et al. · Chemistry & Biology | May 2010 | 1,865 |
| 33 | DNA TOPOISOMERASES James C. Wang · Annual Review of Biochemistry | Jun 1996 | 1,839 |
| 34 | Targeting DNA topoisomerase II in cancer chemotherapy John L. Nitiss · Nature reviews. Cancer | 20 Apr 2009 | 1,827 |
| 35 | Mechanisms of Multidrug Resistance in Cancer Chemotherapy Karol Bukowski, Mateusz Kciuk, Renata Kontek · International Journal of Molecular Sciences | 2 May 2020 | 1,812 |
| 36 | Antibiotics for Emerging Pathogens Michael Andrew Fischbach, Christopher T. Walsh · Science | 27 Aug 2009 | 1,791 |
| 37 | CYTOCHEMICAL DEMONSTRATION OF SUCCINIC DEHYDROGENASE BY THE USE OF A NEW p-NITROPHENYL SUBSTITUTED DITETRAZOLE Marvin M. Nachlas, K. C. Tsou, EUSTACE DE SOUZA et al. · Journal of Histochemistry & Cytochemistry | Jul 1957 | 1,773 |
| 38 | DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy Ken André Olaussen, Ariane Dunant, Pierre Jean Fouret et al. · New England Journal of Medicine | 6 Sep 2006 | 1,745 |
| 39 | Quinoline, quinazoline and acridonealkaloids Joseph P. Michael · Natural Product Reports | 17 Dec 2007 | 1,721 |
| 40 | Molecular mechanisms of drug resistance DB Longley, PG Johnston · The Journal of Pathology | 2005 | 1,690 |
| 41 | Small-cell lung cancer Charles M. Rudin, Elisabeth M. Brambilla, Corinne Faivre Finn et al. · Nature Reviews Disease Primers | 14 Jan 2021 | 1,632 |
| 42 | γH2AX and cancer William M. Bonner, Christophe E. Redon, Jennifer S. Dickey et al. · Nature reviews. Cancer | 13 Nov 2008 | 1,632 |
| 43 | γH2AX: a sensitive molecular marker of DNA damage and repair L-J Mah, Assam El‐Osta, Tom C. Karagiannis · Leukemia | 4 Feb 2010 | 1,595 |
| 44 | Molecular mechanisms that confer antibacterial drug resistance Christopher T. Walsh · Nature | 17 Aug 2000 | 1,587 |
| 45 | Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen Michael R. Boyd, Kenneth D. Paull · Drug Development Research | Feb 1995 | 1,565 |
| 46 | Expression of a multidrug-resistance gene in human tumors and tissues. Antonio Tito Fojo, Kazumitsu Ueda, Dennis J. Slamon et al. · Proceedings of the National Academy of Sciences | 1987 | 1,555 |
| 47 | Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II K M Tewey, Thomas C. Rowe, Liu Yang et al. · Science | 26 Oct 1984 | 1,551 |
| 48 | Double-Strand Break End Resection and Repair Pathway Choice Lorraine S. Symington, Jean Gautier · Annual Review of Genetics | 2 Mar 2011 | 1,540 |
| 49 | Autoradiographic Study of Cell Migration during Histogenesis of Cerebral Cortex in the Mouse Jay B. Angevine, Richard L. Sidman · Nature | Nov 1961 | 1,537 |
| 50 | Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer Robert J. Mayer et al. · New England Journal of Medicine | 13 May 2015 | 1,457 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.